| abstract |
Disclosed are indazol-amino-quinazolin derivatives of formula (I), pharmaceutically acceptable salt and hydrate thereof, wherein the variables are as defined in the specification. These compounds are suitable for inhibiting the activity of a Rho kinase and are useful for treating cancer, neuronal degeneration (peripheral or central), spinal cord injury, erectile dysfunction, atherosclerosis, hypertension, cerebral vasospasm, cerebral ischemia, restenosis, asthma, glaucoma, asthma, osteoporosis, fibrotic disease (liver and kidney), kidney dialysis (epithelial stability), neuronal degeneration and inflammation. |